merryshmuck is trying to distract us here. Amgen had a failed attempt at small molecule shop, which became Array. Now Amgen is developing a small molecule which Array discovered and licensed to them - AMG151. Check out the clinical trials dot gov. They just completed Ph 2 two weeks ago. If the results are good then Amgen should gobble up Array before going Ph 3, instead of paying royalties later.